These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34820591)

  • 21. Towards FAIRification of sensitive and fragmented rare disease patient data: challenges and solutions in European reference network registries.
    Dos Santos Vieira B; Bernabé CH; Zhang S; Abaza H; Benis N; Cámara A; Cornet R; Le Cornec CMA; 't Hoen PAC; Schaefer F; van der Velde KJ; Swertz MA; Wilkinson MD; Jacobsen A; Roos M
    Orphanet J Rare Dis; 2022 Dec; 17(1):436. PubMed ID: 36517834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. From papers to RDF-based integration of physicochemical data and adverse outcome pathways for nanomaterials.
    van Rijn JPM; Martens M; Ammar A; Cimpan MR; Fessard V; Hoet P; Jeliazkova N; Murugadoss S; Vinković Vrček I; Willighagen EL
    J Cheminform; 2024 May; 16(1):49. PubMed ID: 38693555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perspectives from the NanoSafety Modelling Cluster on the validation criteria for (Q)SAR models used in nanotechnology.
    Puzyn T; Jeliazkova N; Sarimveis H; Marchese Robinson RL; Lobaskin V; Rallo R; Richarz AN; Gajewicz A; Papadopulos MG; Hastings J; Cronin MTD; Benfenati E; Fernández A
    Food Chem Toxicol; 2018 Feb; 112():478-494. PubMed ID: 28943385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Why adverse outcome pathways need to be FAIR.
    Wittwehr C; Clerbaux LA; Edwards S; Angrish M; Mortensen H; Carusi A; Gromelski M; Lekka E; Virvilis V; Martens M; Bonino da Silva Santos LO; Nymark P
    ALTEX; 2024 Jan; 41(1):50-56. PubMed ID: 37528748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FAIR in action - a flexible framework to guide FAIRification.
    Welter D; Juty N; Rocca-Serra P; Xu F; Henderson D; Gu W; Strubel J; Giessmann RT; Emam I; Gadiya Y; Abbassi-Daloii T; Alharbi E; Gray AJG; Courtot M; Gribbon P; Ioannidis V; Reilly DS; Lynch N; Boiten JW; Satagopam V; Goble C; Sansone SA; Burdett T
    Sci Data; 2023 May; 10(1):291. PubMed ID: 37208349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predicting 30-Day Readmission Risk for Patients With Chronic Obstructive Pulmonary Disease Through a Federated Machine Learning Architecture on Findable, Accessible, Interoperable, and Reusable (FAIR) Data: Development and Validation Study.
    Alvarez-Romero C; Martinez-Garcia A; Ternero Vega J; Díaz-Jimènez P; Jimènez-Juan C; Nieto-Martín MD; Román Villarán E; Kovacevic T; Bokan D; Hromis S; Djekic Malbasa J; Beslać S; Zaric B; Gencturk M; Sinaci AA; Ollero Baturone M; Parra Calderón CL
    JMIR Med Inform; 2022 Jun; 10(6):e35307. PubMed ID: 35653170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing.
    Tice RR; Agurell E; Anderson D; Burlinson B; Hartmann A; Kobayashi H; Miyamae Y; Rojas E; Ryu JC; Sasaki YF
    Environ Mol Mutagen; 2000; 35(3):206-21. PubMed ID: 10737956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FAIR data station for lightweight metadata management and validation of omics studies.
    Nijsse B; Schaap PJ; Koehorst JJ
    Gigascience; 2022 Dec; 12():. PubMed ID: 36879493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PROTEOMAS: a workflow enabling harmonized proteomic meta-analysis and proteomic signature mapping.
    Bahl A; Ibrahim C; Plate K; Haase A; Dengjel J; Nymark P; Dumit VI
    J Cheminform; 2023 Mar; 15(1):34. PubMed ID: 36935498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New methodological developments for testing the in vitro genotoxicity of nanomaterials: Comparison of 2D and 3D HepaRG liver cell models and classical and high throughput comet assay formats.
    Varet J; Barranger A; Crochet C; Huet S; Hogeveen K; Le Hégarat L; Fessard V
    Chemosphere; 2024 Feb; 350():140975. PubMed ID: 38142884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of the European centre for the validation of alternative methods (ECVAM) in the validation of (Q)SARs.
    Worth AP; Hartung T; Van Leeuwen CJ
    SAR QSAR Environ Res; 2004; 15(5-6):345-58. PubMed ID: 15669694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [FAIR health data in the national and international data space].
    Waltemath D; Beyan O; Crameri K; Dedié A; Gierend K; Gröber P; Inau ET; Michaelis L; Reinecke I; Sedlmayr M; Thun S; Krefting D
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2024 Jun; 67(6):710-720. PubMed ID: 38750239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of the European Chemicals Bureau in promoting the regulatory use of (Q)SAR methods.
    Worth AP; Bassan A; De Bruijn J; Gallegos Saliner A; Netzeva T; Patlewicz G; Pavan M; Tsakovska I; Eisenreich S
    SAR QSAR Environ Res; 2007; 18(1-2):111-25. PubMed ID: 17365963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erratum: Eyestalk Ablation to Increase Ovarian Maturation in Mud Crabs.
    J Vis Exp; 2023 May; (195):. PubMed ID: 37235796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Making in silico predictive models for toxicology FAIR.
    Cronin MTD; Belfield SJ; Briggs KA; Enoch SJ; Firman JW; Frericks M; Garrard C; Maccallum PH; Madden JC; Pastor M; Sanz F; Soininen I; Sousoni D
    Regul Toxicol Pharmacol; 2023 May; 140():105385. PubMed ID: 37037390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Computer models versus reality: how well do in silico models currently predict the sensitization potential of a substance.
    Teubner W; Mehling A; Schuster PX; Guth K; Worth A; Burton J; van Ravenzwaay B; Landsiedel R
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):468-85. PubMed ID: 24090701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A FAIR-Decide framework for pharmaceutical R&D: FAIR data cost-benefit assessment.
    Alharbi E; Skeva R; Juty N; Jay C; Goble C
    Drug Discov Today; 2023 Apr; 28(4):103510. PubMed ID: 36716952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Health data collection methods and procedures across EU member states: findings from the InfAct Joint Action on health information.
    Unim B; Mattei E; Carle F; Tolonen H; Bernal-Delgado E; Achterberg P; Zaletel M; Seeling S; Haneef R; Lorcy AC; Van Oyen H; Palmieri L
    Arch Public Health; 2022 Jan; 80(1):17. PubMed ID: 34986889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Minderoo-Monaco Commission on Plastics and Human Health.
    Landrigan PJ; Raps H; Cropper M; Bald C; Brunner M; Canonizado EM; Charles D; Chiles TC; Donohue MJ; Enck J; Fenichel P; Fleming LE; Ferrier-Pages C; Fordham R; Gozt A; Griffin C; Hahn ME; Haryanto B; Hixson R; Ianelli H; James BD; Kumar P; Laborde A; Law KL; Martin K; Mu J; Mulders Y; Mustapha A; Niu J; Pahl S; Park Y; Pedrotti ML; Pitt JA; Ruchirawat M; Seewoo BJ; Spring M; Stegeman JJ; Suk W; Symeonides C; Takada H; Thompson RC; Vicini A; Wang Z; Whitman E; Wirth D; Wolff M; Yousuf AK; Dunlop S
    Ann Glob Health; 2023; 89(1):23. PubMed ID: 36969097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concern-driven integrated approaches to nanomaterial testing and assessment--report of the NanoSafety Cluster Working Group 10.
    Oomen AG; Bos PM; Fernandes TF; Hund-Rinke K; Boraschi D; Byrne HJ; Aschberger K; Gottardo S; von der Kammer F; Kühnel D; Hristozov D; Marcomini A; Migliore L; Scott-Fordsmand J; Wick P; Landsiedel R
    Nanotoxicology; 2014 May; 8(3):334-48. PubMed ID: 23641967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.